Amanote Research
Register
Sign In
Role of Nab-Paclitaxel in Metastatic Breast Cancer: A Meta-Analysis of Randomized Clinical Trials
Oncotarget
- United States
doi 10.18632/oncotarget.18900
Full Text
Open PDF
Abstract
Available in
full text
Categories
Oncology
Date
June 30, 2017
Authors
Yun Liu
Guoxin Ye
Dali Yan
Lei Zhang
Fan Fan
Jifeng Feng
Publisher
Impact Journals, LLC
Related search
Quality-Adjusted Survival With Nab -Paclitaxel vs Standard Paclitaxel in Metastatic Breast Cancer: A Q-TWiST Analysis
Clinical Breast Cancer
Cancer Research
Oncology
Nab-Paclitaxel for the Management of Triple-Negative Metastatic Breast Cancer
Anti-Cancer Drugs
Cancer Research
Oncology
Pharmacology
Comparative Effectiveness of Early-Line Nab-Paclitaxel vs. Paclitaxel in Patients With Metastatic Breast Cancer: A US Community-Based Real-World Analysis
Cancer Management and Research
Oncology
Nab-Paclitaxel Monotherapy in Patients With Metastatic Breast Cancer With Visceral Crisis: Evaluation of Efficacy and Tolerability in Clinical Practice
Medical Council
Caveolin-1 Expression Predicts Efficacy of Weekly Nab-Paclitaxel Plus Gemcitabine for Metastatic Breast Cancer in the Phase II Clinical Trial
BMC Cancer
Cancer Research
Oncology
Genetics
Tumor Reduction in Primary and Metastatic Pancreatic Cancer Lesions With Nab-Paclitaxel and Gemcitabine
Pancreas
Internal Medicine
Endocrinology
Hepatology
Metabolism
Diabetes
Network Meta-Analysis of Randomized Clinical Trials: Reporting the Proper Summaries
Clinical Trials
Medicine
Pharmacology
Biased Safety Reporting in Blinded Randomized Clinical Trials: Meta-Analysis of Angiotensin Receptor Blocker Trials
PLoS ONE
Multidisciplinary
A Systematic Review of Gemcitabine and Taxanes Combination Therapy Randomized Trials for Metastatic Breast Cancer
SpringerPlus
Multidisciplinary
